FDA Sets Timer for ROMVIMZA Patent Extension Bid
Published Date: 12/29/2025
Notice
Summary
The FDA has set the official review period for the drug ROMVIMZA, which helps the company extend its patent protection. This means the drug maker could get more time to exclusively sell ROMVIMZA, potentially affecting competition and profits. People can challenge the dates or the company’s effort in the review process by early and mid-2026 deadlines.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 0 costs, 1 mixed.
ROMVIMZA review period set
FDA determined ROMVIMZA had a 3,020-day regulatory review period: 2,777 days in the testing phase and 243 days in the approval phase. FDA verified key dates: IND effective November 10, 2016; NDA submitted June 17, 2024; NDA approved February 14, 2025, and the applicant seeks 1,632 days of patent term extension.
Law allows up to 5-year patent extension
Under the governing statutes, a patent may be extended for up to 5 years when the patented product was subject to FDA regulatory review before marketing. FDA's determination of the regulatory review period forms the basis for calculating any extension.
Public deadlines to challenge dates
Anyone who believes the published dates are wrong may ask FDA for a redetermination by February 27, 2026. Any interested person may petition FDA about whether the applicant acted with due diligence during the regulatory review period by June 29, 2026.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in